Introduction: What they say:
A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”
This study was published in the June 25, 2014 Nature [I.F >42] by Prof. Wan Y, Krzeszinski and others from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
What we say:
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiR-1827 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene
From Research findings to Therapeutic utility:
MiR-1827, by down-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis.
Thus, pharmacological formulations encompassing “MiR-1827 or its activators or MiR-1827 activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.
Details of the research findings:
Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase & payment details, you may reach us at email@example.com
Citation: Boominathan, L., Molecular therapy for Bone disorders: MiR-1827 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via down-regulation of its target gene, 8/February/2017, 8.33 am., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org